Company intelligence / Profile preview

Intro Biopharma

Suwon, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

IntroBio is a South Korean biotechnology company focused on developing innovative metabolic and endocrine therapies, with a particular emphasis on oral formulations of traditionally injectable peptides. The company leverages a proprietary drug delivery platform designed to enhance the bioavailability of peptide drugs, targeting high-growth markets such as obesity and type 2 diabetes. Their lead research programs involve multi-agonist peptides, including GLP-1, GIP, and Glucagon receptor agonists. IntroBio aims to improve patient compliance and therapeutic outcomes by transitioning complex biologics into convenient oral dosage forms.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Intro Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intro Biopharma.

Explore the full profile